CV Sciences Receives Formal Notice of Patent Issuance from Japan Patent Office for Formulations Containing Cannabidiol (CBD) and Nicotine for Treating Smokeless Tobacco Addiction
The Company is seeking strategic opportunities to advance the development of this program
SAN DIEGO, March 23, 2023 /PRNewswire/ — CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed, natural ingredients and products, today announced that recently the Company received its formal Certificate of Grant from the Japan Patent Office (JPO) for its patent application 7216697.
Related news for (CVSI)
- CV Sciences, Inc. Enters Into Definitive Agreement to Acquire Extract Labs
- CV Sciences, Inc. To Announce Second Quarter 2024 Results On August 13, 2024
- CV SCIENCES, INC. ACQUIRES ELEVATED SOFTGELS, A FLEXIBLE, LOW-MOQ, NUTRACEUTICAL MANUFACTURER
- CV Sciences, Inc. Reports Fiscal Year-End 2023 Financial Results
- CV Sciences, Inc. Expands +PlusCBD Pet Product Offerings with the Launch of Pet Chews